<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Norethindrone: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Norethindrone: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Norethindrone: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="10173" href="/d/html/10173.html" rel="external">see "Norethindrone: Drug information"</a> and <a class="drug drug_patient" data-topicid="11809" href="/d/html/11809.html" rel="external">see "Norethindrone: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F202477"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Aygestin [DSC];</li>
<li>Camila;</li>
<li>Deblitane;</li>
<li>Errin;</li>
<li>Heather;</li>
<li>Incassia;</li>
<li>Jencycla;</li>
<li>Lyleq;</li>
<li>Lyza;</li>
<li>Nora-BE;</li>
<li>Norlyda [DSC];</li>
<li>Norlyroc;</li>
<li>Ortho Micronor [DSC];</li>
<li>Sharobel;</li>
<li>Tulana [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57397453"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Jencycla;</li>
<li>Maeve;</li>
<li>Micronor [DSC];</li>
<li>Movisse;</li>
<li>Norlutate</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1060617"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Contraceptive, Oral</span>;</li>
<li>
<span class="list-set-name">Contraceptive, Progestin Only</span>;</li>
<li>
<span class="list-set-name">Progestin</span></li></ul></div>
<div class="block dop drugH1Div" id="F202494"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="795c2b16-96ab-4b32-b9a7-a5779db323e3">Abnormal uterine bleeding and amenorrhea</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Abnormal uterine bleeding and amenorrhea (secondary):</b> Postmenarche females: Limited data in postmenarche children: Norethindrone acetate: Oral: 2.5 to 10 mg once daily for 5 to 12 days each month; most pediatric experts suggest 5 mg once daily for 12 days per month (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kliegman.3','lexi-content-ref-Kliegman.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kliegman.3','lexi-content-ref-Kliegman.2'])">Ref</a></span>). Secretory transformation of the endometrium will occur when adequately primed with endogenous or exogenous estrogen. Withdrawal bleeding may be expected within 3 to 7 days after discontinuing norethindrone acetate.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d8874c8-e0f3-47c9-a18f-f794ce8d5154">Contraception</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Contraception: </b>Postmenarche adolescent females: Norethindrone: Oral: 0.35 mg once daily every day (no missed days)</p>
<p style="text-indent:-2em;margin-left:4em;">Initial dose: Start on first day of menstrual period or the day after a miscarriage or abortion. If switching from a combined oral contraceptive, begin the day after finishing the last active combined tablet.</p>
<p style="text-indent:-2em;margin-left:4em;">Missed dose: Take as soon as remembered. A back-up method of contraception should be used for 48 hours if dose is taken ≥3 hours late.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Additional contraception dosing considerations </i>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27467319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27467319'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Initiation of therapy: May be started at any time in the menstrual cycle once it is determined that the female is not pregnant. Back-up contraception is not needed if started within 5 days of onset of menstruation. If started &gt;5 days after the onset of menstruation or at any time in a female experiencing amenorrhea (not postpartum), back up contraception should be used for 2 days.</p>
<p style="text-indent:-2em;margin-left:6em;">Switching from a different contraceptive to a progestin-only contraceptive: May be started at any time if it is determined that the female is not pregnant. Unless the female abstains from sexual intercourse, a back-up method of contraception is needed if it has been &gt;5 days since menstrual bleeding has begun. When an additional method of contraception is needed, consider continuing the woman’s previous method for 2 days after starting the progestin-only contraceptive.</p>
<p style="text-indent:-2em;margin-left:6em;">Switching from an IUD to a progestin-only contraceptive: Continue the IUD for at least 2 days after the progestin-only contraceptive is started or advise the female to abstain from sexual intercourse or use a barrier contraceptive for 7 days before removing the IUD. Alternately, an emergency contraceptive may be used at the time of IUD removal.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46c9c161-3a00-43b9-b6a4-9d35ba3a22b8">Endometriosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometriosis:</b> Postmenarche females ≥10 years: Limited data in children 10 to 12 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22154396']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22154396'])">Ref</a></span>): Norethindrone acetate: Oral: 5 mg once daily for 14 days; increase at increments of 2.5 mg/day every 2 weeks to reach target maintenance of 15 mg/day; continue for 6 to 9 months or until breakthrough bleeding demands temporary termination</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51131258"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51131259"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, use is contraindicated in patients with hepatic tumors or impairment.</p></div>
<div class="block doa drugH1Div" id="F202480"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="10173" href="/d/html/10173.html" rel="external">see "Norethindrone: Drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Norethindrone (NET) is used for progestin-only contraception. Norethindrone <b>acetate </b>(NETA) is a prodrug of NET used in treatment of abnormal uterine bleeding, amenorrhea, and endometriosis. NET and NETA have different dosing, warnings, and precautions; confirm appropriate formulation before prescribing. <b>
<i>International considerations:</i></b> Different preparations (with different dosing and indications) are available outside of the United States.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="fae0ae65-c96c-4591-ade4-935b592626f5">Abnormal uterine bleeding, acute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Abnormal uterine bleeding, acute (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Hemodynamically unstable patients should generally be managed with surgical interventions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23635706','lexi-content-ref-Zacur.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23635706','lexi-content-ref-Zacur.1'])">Ref</a></span>). Typically used for hemodynamically stable patients with anovulatory bleeding and a thickened endometrium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31441825','lexi-content-ref-Zacur.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31441825','lexi-content-ref-Zacur.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral</b>: Norethindrone <b>acetate</b> (NETA): 5 to 10 mg 1 to 4 times a day for 5 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31441825','lexi-content-ref-Zacur.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31441825','lexi-content-ref-Zacur.1'])">Ref</a></span>). <b>Note: </b>Transition to maintenance dosing after resolution of acute bleeding (refer to dosing for “Abnormal uterine bleeding, nonacute”) or to another type of progestin (eg, levonorgestrel IUD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31441825','lexi-content-ref-Kaunitz.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31441825','lexi-content-ref-Kaunitz.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0aa64061-6e3a-4e32-801e-0989bd1fbc53">Abnormal uterine bleeding, nonacute</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Abnormal uterine bleeding, nonacute (alternative agent):</b>
<b>Note:</b> Dosing not intended for management of acute abnormal bleeding (ie, excessively heavy or prolonged bleeding that requires urgent evaluation). Alternative for patients who cannot or choose not to use preferred agents (eg, estrogen-progestin contraceptives, levonorgestrel IUD) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kaunitz.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kaunitz.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Norethindrone <b>acetate </b>(NETA): 5 to 15 mg per day in 1 to 3 divided doses; adjust dose at 1- to 3-month intervals within this range to the lowest effective dose to control bleeding and minimize adverse reactions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31441825','lexi-content-ref-Kaunitz.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31441825','lexi-content-ref-Kaunitz.1'])">Ref</a></span>). <b>Note: </b>Continuous therapy is preferred in most patients due to increased efficacy and patient adherence; however, for patients who do not desire contraception, cyclic therapy (eg, administration only on days 5 to 26 of the menstrual cycle) may be preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22067765','lexi-content-ref-31535715','lexi-content-ref-9647148','lexi-content-ref-Kaunitz.1','lexi-content-ref-30742315','lexi-content-ref-34214420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22067765','lexi-content-ref-31535715','lexi-content-ref-9647148','lexi-content-ref-Kaunitz.1','lexi-content-ref-30742315','lexi-content-ref-34214420'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0d8874c8-e0f3-47c9-a18f-f794ce8d5154">Contraception</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Contraception:</b>
<b>Oral:</b> Norethindrone (NET): 0.35 mg once daily in the order presented in the blister pack (no missed days).</p>
<p style="text-indent:-2em;margin-left:4em;">Initial dose: Start on first day of menstrual period or the day after a miscarriage or abortion. If switching from a combined oral contraceptive, begin the day after finishing the last active combined tablet.</p>
<p style="text-indent:-2em;margin-left:4em;">Missed dose: Take as soon as remembered. A back up method of contraception should be used for 48 hours if dose is taken ≥3 hours late.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Additional contraception dosing considerations</i> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27467319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27467319'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:6em;">Initiation of therapy: May be started at any time in the menstrual cycle once it is determined that the patient is not pregnant. Back-up contraception is not needed if started within 5 days of onset of menstruation. If started &gt;5 days after the onset of menstruation or at any time in a patient experiencing amenorrhea (not postpartum), back up contraception should be used for 2 days.</p>
<p style="text-indent:-2em;margin-left:6em;">Switching from a different contraceptive to a progestin-only contraceptive: May be started at any time if it is determined that the patient is not pregnant. Unless the patient abstains from sexual intercourse, a backup method of contraception is needed if it has been &gt;5 days since menstrual bleeding has begun. When an additional method of contraception is needed, consider continuing the patient's previous method for 2 days after starting the progestin-only contraceptive.</p>
<p style="text-indent:-2em;margin-left:6em;">Switching from an IUD to a progestin-only contraceptive: Continue the IUD for at least 2 days after the progestin-only contraceptive is started or advise the patient to abstain from sexual intercourse or use a barrier contraceptive for 7 days before removing the IUD. Alternately, an emergency contraceptive may be used at the time of IUD removal.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="46c9c161-3a00-43b9-b6a4-9d35ba3a22b8">Endometriosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Endometriosis:</b>
<b>Oral:</b> Norethindrone <b>acetate </b>(NETA): 5 mg/day for 14 days; increase at increments of 2.5 mg/day every 2 weeks to reach 15 mg/day; continue for 6 to 9 months or until breakthrough bleeding demands temporary termination.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a0dc7166-0057-472c-ba10-74443d45e282">Estrogen therapy-associated endometrial hyperplasia, prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Estrogen therapy-associated endometrial hyperplasia, prevention (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Indicated in patients with a uterus receiving estrogen therapy (eg, for secondary amenorrhea) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28368518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28368518'])">Ref</a></span>). Discontinue when estrogen therapy is discontinued.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Norethindrone <b>acetate </b>(NETA): 5 to 10 mg/day for 10 to 14 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Ackerman.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Ackerman.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="40029beb-aba6-467e-b908-d4431aca5c40">Secondary amenorrhea, diagnostic aid</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Secondary amenorrhea, diagnostic aid ("progestin challenge") (alternative agent): Oral:</b> Norethindrone acetate (NETA): 5 mg daily for 5 to 10 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28368518']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28368518'])">Ref</a></span>). <b>Note:</b> Withdrawal bleeding may be expected during therapy or within 3 to 7 days after cessation of therapy; absence of withdrawal bleeding suggests low endometrial estrogen exposure and/or uterine or outflow tract abnormality (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28368518','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28368518','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991667"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50988975"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling. However, use is contraindicated in patients with hepatic tumors or impairment.</p></div>
<div class="block arsc drugH1Div" id="F58569778"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Menstrual bleeding irregularities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Norethindrone may cause menstrual bleeding irregularities (<b>change in menstrual flow</b>), including shortened or prolonged menstrual cycles, <b>amenorrhea</b>, and/or <b>spotting</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12046776','lexi-content-ref-29386936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12046776','lexi-content-ref-29386936'])">Ref</a></span>). Menstrual bleeding irregularities are the most common reason for drug discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24315714','lexi-content-ref-29386936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24315714','lexi-content-ref-29386936'])">Ref</a></span>). Menstrual bleeding irregularities may be experienced by up to 50% of users with 10% experiencing amenorrhea (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24315714','lexi-content-ref-29386936']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24315714','lexi-content-ref-29386936'])">Ref</a></span>). Consistent medication administration minimizes changes in bleeding patterns, as variances of 2 to 3 hours in administration may cause menstrual bleeding irregularities (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31138184','lexi-content-ref-24315714','lexi-content-ref-12046776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31138184','lexi-content-ref-24315714','lexi-content-ref-12046776'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; short half-life and weak suppression of the hypothalamic-pituitary-ovarian axis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31138184','lexi-content-ref-12046776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31138184','lexi-content-ref-12046776'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; menstrual bleeding irregularities are most likely experienced in the first 3 months of therapy. However, daily variations in dose administration may be a continued source of irregular patterns (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31138184','lexi-content-ref-12046776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31138184','lexi-content-ref-12046776'])">Ref</a></span>). One missed dose may cause withdrawal bleeding in 24 to 72 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31138184']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31138184'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Inconsistent time of drug administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31138184','lexi-content-ref-24315714','lexi-content-ref-12046776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31138184','lexi-content-ref-24315714','lexi-content-ref-12046776'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F202451"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions are derived from product labeling unless otherwise specified. Reactions listed are based on reports for other agents in this same pharmacologic class and may not be specifically reported for norethindrone.</p>
<p style="text-indent:0em;">Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Deep vein thrombosis, edema, pulmonary embolism</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, alopecia, chloasma, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased HDL cholesterol, heavy menstrual bleeding, hirsutism, spotting, weight gain, weight loss</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Breakthrough bleeding, breast hypertrophy, breast tenderness, cervical erosion, change in cervical secretions, genital discharge, infrequent uterine bleeding, lactation insufficiency, mastalgia, vaginal hemorrhage</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests, cholestatic jaundice, hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, hypersensitivity reaction, nonimmune anaphylaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Cerebral artery embolism, cerebral thrombosis, depression, dizziness, emotional lability, fatigue, headache, insomnia, migraine, nervousness</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Limb pain</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Optic neuritis (with or without vision loss), retinal thrombosis</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Endocrine &amp; metabolic: Amenorrhea (Santos 2014), change in menstrual flow (Santos 2014)</p></div>
<div class="block coi drugH1Div" id="F202461"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to norethindrone or any component of the formulation; breast cancer (known, suspected, or history of); undiagnosed abnormal genital bleeding; pregnancy.</p>
<p style="text-indent:-2em;margin-left:2em;">Norethindrone (NET): Additional contraindications: Benign or malignant liver tumors; acute liver disease.</p>
<p style="text-indent:-2em;margin-left:2em;">Norethindrone <b>acetate</b> (NETA):</p>
<p style="text-indent:-2em;margin-left:4em;">Additional contraindications: Deep vein thrombosis or pulmonary embolism (current or history of); active or recent history of arterial thromboembolic disease (eg, stroke, myocardial infarction); hepatic impairment or disease; as a diagnostic test for pregnancy.</p>
<p style="text-indent:-2em;margin-left:4em;">Additional contraindications in Canadian labeling: Estrogen or progestin dependent malignant tumor; partial or complete vision loss due to ophthalmic vascular disease; missed abortion.</p></div>
<div class="block war drugH1Div" id="F202448"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Delayed follicular atresia/ovarian cysts: If follicular development occurs following use for contraception, follicles may grow and enlarge beyond the size attained in a normal cycle. May be asymptomatic or can be associated with mild abdominal pain; surgical intervention is rarely required.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ectopic pregnancy: The possibility of ectopic pregnancy following use of a progestin-only contraceptive should be considered in patients with lower abdominal pain.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic adenomas or carcinomas: Use of combination hormonal contraceptives is associated with hepatic adenomas (rare); rupture may cause fatal intra-abdominal hemorrhage. Long-term use may be associated with an increased risk of hepatocellular carcinoma (rare). Data are insufficient to determine if progestin-only contraceptives also increase this risk.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lipid effects: May have adverse effects on lipid metabolism; use caution in patients with hyperlipidemias.</p>
<p style="text-indent:-2em;margin-left:4em;">• Visual abnormalities: Norethindrone<b> acetate </b>(NETA): Discontinue if migraine, loss of vision, proptosis, diplopia, or other visual disturbances occur; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer: In patients at risk for breast cancer due to family history or susceptibility genes (<i>BRCA1, BRCA2</i>), it is unclear if combination hormonal contraceptives increase the risk for breast cancer and there are insufficient data specific to progestin-only contraceptives. However, breast cancer is a hormonal-sensitive tumor and the prognosis for patients with a current or recent history of breast cancer may be worse with hormonal contraceptive use (CDC [Curtis 2016b]; SGO/ASRM [Chen 2019]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Norethindrone <b>acetate </b>(NETA): Risk factors for cardiovascular disorders include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Manage risk factors appropriately.</p>
<p style="text-indent:-2em;margin-left:4em;">• Depression: Norethindrone <b>acetate </b>(NETA): Use with caution in patients with depression. Progestin-only contraceptive tablets may be used in patients with depression (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: May have adverse effects on glucose tolerance; use caution in patients with diabetes. Progestin-only contraceptive tablets may be used in patients with diabetes (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Diseases exacerbated by fluid retention: Norethindrone <b>acetate </b>(NETA): Use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, or cardiac or renal dysfunction.</p>
<p style="text-indent:-2em;margin-left:4em;">• Migraine: Use with caution in patients with a history of migraine. Progestin-only contraceptive tablets may be used in patients with a history of headache or migraine; new headaches or changes in headaches should be evaluated (CDC [Curtis 2016b]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Smoking: Progestin-only contraceptives may be used in patients who smoke (CDC [Curtis 2016b]). Because of an increased risk of cardiovascular disease, patients using oral contraceptives should be strongly advised not to smoke.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Norethindrone (NET): Progestin-only contraceptives contain less progestogen than contained in estrogen/progestogen–combined contraceptives. Risks associated with estrogen/progestogen contraceptives should be considered for progestin-only products.</p>
<p style="text-indent:-2em;margin-left:4em;">• HIV infection protection: Progestin-only contraceptives do not protect against HIV infection or other sexually transmitted diseases.</p></div>
<div class="block foc drugH1Div" id="F202457"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Camila: 0.35 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Camila: 0.35 mg [contains corn starch, fd&amp;c red #40(allura red ac)aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Deblitane: 0.35 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake, soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Errin: 0.35 mg [contains corn starch, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Heather: 0.35 mg [contains fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Incassia: 0.35 mg [contains corn starch, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jencycla: 0.35 mg [contains fd&amp;c blue #1 (brilliant blue), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lyleq: 0.35 mg [contains corn starch, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lyza: 0.35 mg [contains corn starch, quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Nora-BE: 0.35 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Norlyda: 0.35 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Norlyroc: 0.35 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ortho Micronor: 0.35 mg [DSC] [contains corn starch, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Sharobel: 0.35 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c yellow #6(sunset yellow)alumin lake, soybean lecithin]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Tulana: 0.35 mg [DSC] [contains corn starch, fd&amp;c yellow #6(sunset yellow)alumin lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.35 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Aygestin: 5 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 5 mg</p></div>
<div class="block geq drugH1Div" id="F202444"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F202462"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Camila Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.35 mg (per each): $1.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Deblitane Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.35 mg (per each): $1.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Errin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.35 mg (per each): $1.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Heather Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.35 mg (per each): $1.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Incassia Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.35 mg (per each): $1.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Jencycla Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.35 mg (per each): $1.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lyleq Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.35 mg (per each): $1.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lyza Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.35 mg (per each): $1.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Nora-BE Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.35 mg (per each): $1.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Norethindrone Acetate Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $2.65</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Norethindrone Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.35 mg (per each): $1.32</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Norlyroc Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.35 mg (per each): $3.96</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sharobel Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.35 mg (per each): $1.32</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57397454"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Jencycla: 0.35 mg [contains fd&amp;c blue #1 (brill blue) aluminum lake, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Maeve: 0.35 mg [contains corn starch, quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Micronor: 0.35 mg [DSC] [contains quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Movisse: 0.35 mg [contains fd&amp;c blue #1 (brilliant blue), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Norlutate: 5 mg [contains corn starch, quinoline yellow (d&amp;c yellow #10)]</p></div>
<div class="block admp drugH1Div" id="F52613445"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer at the same time each day</p>
<p style="text-indent:-2em;margin-left:2em;">When used for the prevention of pregnancy, a back-up method of contraception should be used for 48 hours if dose is missed or taken ≥3 hours late. If vomiting or severe diarrhea occur within 3 hours of taking a dose, take another dose as soon as possible, then continue taking one dose daily and use a backup method of contraception (or avoid sexual intercourse) until 2 days after vomiting or diarrhea have resolved. Emergency contraception should be considered in the event of unprotected intercourse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23784109']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23784109'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F803179"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Ora</b>
<b>l:</b> For oral administration. Administer at the same time each day.</p>
<p style="text-indent:-2em;margin-left:2em;">When used for the prevention of pregnancy, a backup method of contraception should be used for 48 hours if dose is missed or taken ≥3 hours late. If vomiting or severe diarrhea occur within 3 hours of taking a dose, take another dose as soon as possible, then continue taking one dose daily and use a backup method of contraception (or avoid sexual intercourse) until 2 days after vomiting or diarrhea have resolved. Emergency contraception should be considered in the event of unprotected intercourse (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27467319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27467319'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49322208"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F6202484"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at controlled room temperature.</p></div>
<div class="block usep drugH1Div" id="F53568061"><span class="drugH1">Use</span>
<p style="text-indent:-2em;margin-left:2em;">Norethindrone: Prevention of pregnancy (FDA approved in postmenarche pediatric and adult females); <b>Note:</b> Not indicated for emergency contraception.</p>
<p style="text-indent:-2em;margin-left:2em;">Norethindrone acetate: Treatment of amenorrhea, endometriosis, and abnormal uterine bleeding (FDA approved in postmenarche pediatric and adult females) <b></b></p></div>
<div class="block mst drugH1Div" id="F202514"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Micronor may be confused with miconazole, Micronase</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Norethindrone (NET) and norethindrone <b>acetate</b> (NETA) may both be available as 5 mg tablets outside of the United States; these products are not equivalent and have different dosing and indications; confirm appropriate formulation before prescribing.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F202506"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F202452"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Adalimumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aprepitant: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration with aprepitant, and to continue back-up contraception for 28 days after discontinuing aprepitant to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asparaginase Products: Hormonal Contraceptives may enhance the thrombogenic effect of Asparaginase Products.  Management: Consider discontinuing hormonal contraceptives and using an alternative contraceptive method in patients treated with asparaginase products.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: May decrease the serum concentration of Hormonal Contraceptives. Management: Use of a high-dose oral contraceptive (at least 30 mcg of ethinyl estradiol combined with norethindrone) is recommended when combined with asunaprevir. Consider an additional barrier method when other forms of contraception are used with asunaprevir.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: May decrease the serum concentration of Hormonal Contraceptives. Specifically, atazanavir/ritonavir may decrease concentrations of estrogens. Atazanavir may increase the serum concentration of Hormonal Contraceptives. Specifically, atazanavir alone may increase concentrations of estrogens and atazanavir alone or boosted may increase concentrations of progestins. Management: Dose adjustment of hormonal contraceptives or use of alternative or additional nonhormonal contraceptive may be needed when combined with atazanavir. See full interact monograph for details. Atazanavir/cobicistat with drospirenone is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bimekizumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May decrease the serum concentration of Hormonal Contraceptives. Management: Use a non-hormonal contraceptive during brigatinib use and for at least 4 months after the last brigatinib dose. Males with partners of reproductive potential should use contraception during treatment with brigatinib and for 3 months after brigatinib use.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carfilzomib: Hormonal Contraceptives may enhance the thrombogenic effect of Carfilzomib.  Management: Consider alternative, non-hormonal methods of contraception in patients requiring therapy with carfilzomib, especially patients using carfilzomib in combination with dexamethasone, lenalidomide plus dexamethasone, or daratumumab plus dexamethasone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chlorprothixene: Progestins may enhance the adverse/toxic effect of Chlorprothixene. Progestins may enhance the therapeutic effect of Chlorprothixene. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofazimine: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May decrease the serum concentration of Hormonal Contraceptives. Specifically, cobicistat may decrease serum concentrations of estrogens. Cobicistat may increase the serum concentration of Hormonal Contraceptives. Specifically, cobicistat may increase serum concentrations of progestins. Management: Use alternative or additional nonhormonal forms of contraception when estrogen-containing hormonal contraceptives are combined with cobicistat. Progestin-only contraceptives can be used without back up, but monitor for progestin toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: May enhance the adverse/toxic effect of Hormonal Contraceptives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colesevelam: May decrease the serum concentration of Norethindrone. Management: Oral contraceptives containing ethinyl estradiol and norethindrone should be administered at least 4 hours before colesevelam.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Norethindrone may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a moderate CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a strong CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Weak): May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing a weak CYP3A4 inducer to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Hormonal Contraceptives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efavirenz: May decrease the serum concentration of Hormonal Contraceptives. Management: Use a back-up method during coadministration, and to continue back-up contraception for 12 weeks after stopping efavirenz to ensure contraceptive reliability. Injected depot medroxyprogesterone acetate does not appear to participate in this interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elagolix: Hormonal Contraceptives may diminish the therapeutic effect of Elagolix. Specifically, estrogen-containing hormonal contraceptives may diminish the therapeutic effects of elagolix. Elagolix may decrease the serum concentration of Hormonal Contraceptives. Specifically, concentrations of progestins may be decreased with elagolix therapy. Elagolix may increase the serum concentration of Hormonal Contraceptives. Specifically, concentrations of ethinyl estradiol may be increased with elagolix therapy.  Management: Use an alternative, nonhormonal contraceptive during treatment with elagolix and for at least 28 days following discontinuation of elagolix treatment. Use of elagolix 200 mg twice daily with an estrogen-containing hormonal contraceptive is not recommended<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: Hormonal Contraceptives may enhance the adverse/toxic effect of Elexacaftor, Tezacaftor, and Ivacaftor. Specifically, the risk for rash may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: May decrease the serum concentration of Hormonal Contraceptives. Specifically, progestin concentrations may decrease. Etravirine may increase the serum concentration of Hormonal Contraceptives. Specifically, estrogen concentrations may increase.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Exenatide: Hormonal Contraceptives may diminish the therapeutic effect of Exenatide. Exenatide may decrease the serum concentration of Hormonal Contraceptives.  Management: Administer oral hormonal contraceptives at least one hour prior to exenatide. Monitor blood glucose more frequently when patients treated with exenatide initiate therapy with a hormonal contraceptive. Increases in exenatide doses may be needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Felbamate: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing felbamate to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: Hormonal Contraceptives may increase the serum concentration of Flibanserin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosaprepitant: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration with fosaprepitant, and to continue back-up contraception for 28 days after discontinuing fosaprepitant to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fusidic Acid (Systemic): May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Griseofulvin: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing griseofulvin to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Interleukin-6 (IL-6) Inhibiting Therapies: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivosidenib: May decrease the serum concentration of Hormonal Contraceptives. Management: Consider alternative methods of contraception (ie, non-hormonal) in patients receiving ivosidenib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ixazomib: May decrease the serum concentration of Hormonal Contraceptives. More specifically, use of ixazomib with dexamethasone may decrease the serum concentrations of hormonal contraceptives. Management: Patients of reproductive potential should use a non-hormonal contraceptive method during treatment with ixazomib and for at least 90 days after the last ixazomib dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lixisenatide: Hormonal Contraceptives may diminish the therapeutic effect of Lixisenatide. Lixisenatide may decrease the serum concentration of Hormonal Contraceptives.  Management: Administer oral hormonal contraceptives 1 hour before or at least 11 hours after administration of lixisenatide. Additionally, monitor blood glucose more frequently when patients treated with lixisenatide initiate therapy with a hormonal contraceptive.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative contraceptive that is not sensitive to CYP3A4 induction or a back-up method during coadministration, and to continue back-up contraception for 4 months after stopping mavacamten to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetyraPONE: Progestins may diminish the diagnostic effect of MetyraPONE.  Management: Consider alternatives to the use of the metyrapone test in patients taking progestins.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">MiFEPRIStone: May diminish the therapeutic effect of Hormonal Contraceptives. Management: Nonhormonal contraception should be used during, and for 4 weeks following, mifepristone treatment for hyperglycemia due to Cushing syndrome. If used for pregnancy termination, hormonal contraceptives can be used after pregnancy expulsion is confirmed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitotane: May decrease the serum concentration of Hormonal Contraceptives. Management: Effective nonhormonal contraception is recommended for those of reproductive potential during treatment with mitotane as well as after discontinuation of mitotane for as long as mitotane plasma levels are detectable.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mobocertinib: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: May decrease the serum concentration of Hormonal Contraceptives. Management: Patients of childbearing potential who are taking hormonal contraceptives should use an additional form of barrier contraception during treatment with mycophenolate and for 6 weeks after mycophenolate discontinuation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May decrease the serum concentration of Hormonal Contraceptives. Specifically, nirmatrelvir and ritonavir may decrease concentrations of estrogens. Nirmatrelvir and Ritonavir may increase the serum concentration of Hormonal Contraceptives. Specifically, nirmatrelvir and ritonavir may increase concentrations of progestins. Management: Use additional nonhormonal forms of contraception (back-up method) when estrogen-containing hormonal contraceptives are combined with nirmatrelvir/ritonavir. Progestin-only contraceptives can be used without back-up, but monitor for progestin toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: May decrease the serum concentration of Hormonal Contraceptives. Management: Women should use an alternative non-hormonal method of contraception or a back-up method when octreotide is combined with hormonal contraceptives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olutasidenib: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers). Management: Avoid use of olutasidenib with sensitive or narrow therapeutic index CYP3A4 substrates when possible. If concurrent use with olutasidenib is unavoidable, monitor closely for evidence of decreased concentrations of the CYP3A4 substrates.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omaveloxolone: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">OXcarbazepine: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing oxcarbazepine to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perampanel: May decrease the serum concentration of Hormonal Contraceptives. Management: Patients should use an alternative, nonhormonal-based form of contraception during the concurrent use of perampanel and for 1 month after discontinuing perampanel.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: May decrease the serum concentration of Hormonal Contraceptives. Management: Patients using hormonal contraception should be advised to use an alternative non-hormonal contraceptive method during treatment with pitolisant and for at least 21 days after discontinuation of pitolisant treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protease Inhibitors: May decrease the serum concentration of Hormonal Contraceptives. Specifically, protease inhibitors may decrease concentrations of estrogens. Protease Inhibitors may increase the serum concentration of Hormonal Contraceptives. Specifically, protease inhibitors may increase concentrations of progestins. Management: Use alternative or additional nonhormonal forms of contraception when estrogen-containing hormonal contraceptives are combined with protease inhibitors. Progestin-only contraceptives can be used without back up, but monitor for progestin toxicities.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Repotrectinib: May decrease the serum concentration of Hormonal Contraceptives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Retinoic Acid Derivatives: May diminish the therapeutic effect of Progestins (Contraceptive). Retinoic Acid Derivatives may decrease the serum concentration of Progestins (Contraceptive). Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives. Microdosed progesterone-only preparations (ie, minipills that do not contain estrogen) are considered an inadequate method of contraception.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sugammadex: May diminish the therapeutic effect of Hormonal Contraceptives. Management: Patients receiving any hormonal contraceptive (oral or non-oral) should use an additional, nonhormonal contraceptive method during and for 7 days following sugammadex treatment.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May decrease the serum concentration of CYP3A4 Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tazemetostat: May decrease the serum concentration of Hormonal Contraceptives. Management: Individuals of childbearing potential should use a non-hormonal contraceptive method during treatment with tazemetostat and for 6 months after. Males with partners of childbearing potential should use contraception during treatment and for 3 months after.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrahydrocannabinol and Cannabidiol: May decrease the serum concentration of Hormonal Contraceptives. Management: Product labeling recommends that patients taking hormonal contraceptives should use an additional, non-hormonal contraceptive or reliable barrier method during treatment with tetrahydrocannabinol and cannabidiol buccal spray.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thalidomide: Hormonal Contraceptives may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tirzepatide: May decrease the serum concentration of Hormonal Contraceptives. Management: Patients using oral hormonal contraceptives should switch to a non-oral contraceptive method, or add a barrier method of contraception, for 4 weeks after initiation of tirzepatide and for 4 weeks after each dose escalation of tirzepatide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Topiramate: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing topiramate to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tranexamic Acid: Hormonal Contraceptives may enhance the thrombogenic effect of Tranexamic Acid. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ulipristal: May diminish the therapeutic effect of Progestins. Progestins may diminish the therapeutic effect of Ulipristal.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ustekinumab: May decrease the serum concentration of CYP Substrates (Narrow Therapeutic Index/Sensitive with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vaborbactam: May decrease the serum concentration of Hormonal Contraceptives. Management: Advise patients to use an alternative method of contraception or a back-up method during coadministration, and to continue back-up contraception for 28 days after discontinuing meropenem/vaborbactam to ensure contraceptive reliability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Hormonal Contraceptives may increase the serum concentration of Vitamin K Antagonists. Hormonal Contraceptives may decrease the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: Hormonal Contraceptives may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Hormonal Contraceptives. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308552"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">
<b>Norethindrone (NET):</b> Progestin-only contraceptives may be started immediately postpartum (CDC [Curtis 2016a]; CDC [Curtis 2016b]). A rapid return to fertility occurs when progestin-only contraceptives are discontinued.</p>
<p style="text-indent:0em;margin-top:2em;">All available forms of contraception, including norethindrone (NET), can be considered for patients on gender affirming testosterone therapy after evaluating patient preferences and medical conditions (eg, risk for venous thromboembolism) (Bonnington 2020; Krempasky 2020).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Norethindrone acetate (NETA):</b> The contraceptive dose of norethindrone <b>acetate</b> is not known. Barrier contraception is recommended to prevent unintended pregnancy (eg, when treating endometriosis) (Kaser 2012). Pregnancy should be excluded prior to inducing withdrawal bleeding with norethindrone <b>acetate</b> (NETA) when evaluating patients for secondary amenorrhea (ES [Gordon 2017]).</p></div>
<div class="block pri drugH1Div" id="F5120967"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">First trimester exposure of progestins may cause genital abnormalities including hypospadias in male infants and mild virilization of external female genitalia. Changes in external genitalia have been reported in female infants exposed to norethindrone <b>acetate</b> (NETA) (Fine 1963). Significant adverse events related to growth and development have not been observed following use of oral progestins in contraceptive doses (limited studies). Use is contraindicated during pregnancy.</p></div>
<div class="block mopp drugH1Div" id="F53568060"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Norethindrone: Contraception: Assessment of pregnancy status (prior to therapy); weight (optional; BMI at baseline may be helpful to monitor changes during therapy); assess potential health status changes at routine visits (Curtis 2016a). Evaluate pregnancy status if 2 consecutive menstrual cycles are missed, or if the menstrual cycle is delayed and ≥1 pill was taken late or missed in a cycle in which intercourse occurred without a back-up method of contraception.</p>
<p style="text-indent:-2em;margin-left:2em;">Norethindrone acetate: Monitor patient for vision changes; signs or symptoms of depression; glycemic control in patients with diabetes; lipid profiles in patients being treated for hyperlipidemias.</p>
<p style="text-indent:-2em;margin-left:2em;">Regardless of indication, adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Pathologist should be informed of therapy when submitting endometrial tissue for histologic evaluation.</p></div>
<div class="block pha drugH1Div" id="F202447"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Once absorbed, systemic disposition of norethindrone <b>acetate</b> (NETA) and norethindrone (NET) is the same.</p>
<p style="text-indent:-2em;margin-left:2em;">NET is used in preparations for progestin-only contraception. NET suppresses ovulation, thickens cervical mucus (which inhibits sperm penetration), alters follicle-stimulating hormone (FSH) and luteinizing hormone (LH) concentrations, slows the movement of ovum through the fallopian tubes, and alters the endometrium.</p>
<p style="text-indent:-2em;margin-left:2em;">Progestogens, such as NETA in the doses used for abnormal uterine bleeding, amenorrhea, and endometriosis, lead to atrophy of the endometrial tissue. They may also suppress new growth and implantation. Pain associated with endometriosis is decreased. When treating endometriosis, NETA may be used in combination with gonadotropin-releasing hormone agonists to decrease side effects from hypoestrogenism (ASRM 2014).</p></div>
<div class="block phk drugH1Div" id="F202460"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Oral: Rapidly absorbed</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 4 L/kg</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 61% to albumin; 36% to sex hormone-binding globulin (SHBG); SHBG capacity affected by plasma ethinyl estradiol levels (Orme 1983)</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Oral: Norethindrone <b>acetate</b> (NETA) is deacetylated to norethindrone; norethindrone undergoes hepatic reduction and conjugation; orally administered norethindrone is subject to first-pass effect (Orme 1983). In addition to forming glucuronide and sulfide conjugates, norethindrone is also metabolized to ethinyl estradiol (Kuhnz 1997; Orme 1983).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 64% (Orme 1983)</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~8 to 9 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: ~2 hours (varies by dose and use of concomitant estrogen (Orme 1983)</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (&gt;50% as metabolites); feces (20% to 40% as metabolites)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F202465"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Primolut n</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Primolut nor | Selectan</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Micronovum</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Locilan | Micronor | Noriday</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Ethinor | Feminor | Menogia | Menoral | Norcolut | Norcutine | Norestin | Normens | Noteron | Primolut n | Remens | Rontril</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Primolut nor</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Norcolut | Primolut nor</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Linatis | Micronor | Norestin | Noretisterona | Primolut nor</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Primolut n</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Fu kang | Norethindrone</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Noristerat | Primolut nor</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Norethisteron | Primolut nor</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Gestakadin | Norethisteron | Primolut nor</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Noriday</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Micronor | Norcolut | Norethisteron | Primolut nor</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cidolut Nor | Noricept | Noristerat | Primolut nor | Steronate</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Primolut nor</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Primolut n</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Mini pill | Primolut n | Primolut nor</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Milligynon | Noristerat</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Menzol | Micronor | Norethisterone | Noriday | Noristerat | Norlutin a | Primolut n | Utovlan</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Fortilut | Primolut nor</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Norcolut | Nordron | Norelut | Normens | Primolut n</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Primolut nor</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Norcolut</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Anore | Luteron | Meprolut | Norelut | Noristerat | Nosthyra | Primolut n | Regumen</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Micronor | Noriday | Primolut n</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Primolut nor</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Amenova | Anbarone | Crina ncr | Cyclenorm P | Cycloreg | Dub | Dubact | Dubnil | Dubogen | Ethinate | Ethinorm p | Ethione cr | Gynabest | Gynaset | Hilnor | Hypogest | Hyston | Martinor | Mendate | Menor n | Mensil n | N ethi | Nc norm p | Neset cr | Nor n | Norate | Norate a | Noreta-hrt | Noreth | Norethea | Norgest | Norglen | Noritis | Norlut-n | Nostra | Nostra CR | Postpon | Preserve-n | Prevent N | Primolut n | Primoriv n | Progeston | Prolin n | Regestrone | Regulate | Secam p | Steranil | Steron | Styptin | Styptin cr | Sysron-n | Trito n | Uninor | Wrolut-n</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Primolut nor</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Aminor | Micronor | Primolut nor</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Norluten | Primolut n</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Dub sterone | Micronor | Ncnorm p | Norcolut | Noristerat | Normens | Noteron | Primolut n | Steron | Strinor</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Primolut n</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Primolut n</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Primolut n | Primolut nor | Steron</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Micronor | Monogest | Noraethisteron | Norcolut | Primolut nor</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Primolut nor</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Monogest | Noraethisteron | Norcolut | Primolut nor</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Milligynon | Noristerat | Norluten | Primolut nor</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Noristerat | Primolut nor | Syngestal</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Depocon | Norcolut | Norcutin | Norelut | Noriday | Noristerat | Normens | Primolut n | Sunolut | Unidepo</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Noristerat | Primolut n</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Primolut n</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Conludag | Primolut n</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Noriday | Primolut n</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Noristerat | Oretes | Primolut n</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Just n | Nesena | Noriday | Norigest | Nova-ject | Postpon m | Primolut n</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Monogest | Norethisteron | Primolut n | Primolut nor</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Aygestin | Camila-28 | Deblitane | Errin-28 | Heather | Incassia | Jencycla | Jolivette-28 | Lyleq | Lyza | Nor-QD | Nora BE | Norethindrone | Norethindrone acetate | Noriday | Norlyda | Ortho Micronor-28 | Sharobel | Tulana</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Primolut nor</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Aminor | Primolut N</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Noristerat</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Norcolut | Primolut nor</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Micronor | Primolut n</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Mini-pe | Noriday | Primolut nor</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Erlisone | Micronor | Norcolut | Norcutin | Sunolut</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Primolut nor</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Norethisteron</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Norca | Norigest | Noristerat | Norterone | Pinrone | Pospond | Primolut n | Steron</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Norluten | Primolut nor</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Primolut n</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Nordron | Noretone | Noruolu | Primolut nor | Shiton | Villfull | Wenisu</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Norcolut | Primolut nor</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Noristerat | Norlut-n | Primolut n</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Primolut nor</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Micro-Novum | Nur isterate | Primolut n</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Knor | Nc norm p | Norelut | Noristerat | Primolut n</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Nur isterate | Primolut n</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22067765">
<a name="22067765"></a>Abu Hashim H, Alsherbini W, Bazeed M. Contraceptive vaginal ring treatment of heavy menstrual bleeding: a randomized controlled trial with norethisterone. <i>Contraception</i>. 2012;85(3):246-252. doi:10.1016/j.contraception.2011.07.012<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/22067765/pubmed" id="22067765" target="_blank">22067765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ackerman.1">
<a name="Ackerman.1"></a>Ackerman KE, Misra M. Functional hypothalamic amenorrhea: Evaluation and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 8, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31603998">
<a name="31603998"></a>Ackerman KE, Singhal V, Slattery M, et al. Effects of estrogen replacement on bone geometry and microarchitecture in adolescent and young adult oligoamenorrheic athletes: a randomized trial. <i>J Bone Miner Res.</i> 2020;35(2):248-260. doi:10.1002/jbmr.3887<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/31603998/pubmed" id="31603998" target="_blank">31603998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27454732">
<a name="27454732"></a>American College of Obstetricians and Gynecologists’ Committee on Adolescent Health Care. Committee Opinion No. 668: Menstrual manipulation for adolescents with physical and developmental disabilities. <i>Obstet Gynecol</i>. 2016;128(2):e20-e25. doi:10.1097/AOG.0000000000001585<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/27454732/pubmed" id="27454732" target="_blank">27454732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36356248">
<a name="36356248"></a>American College of Obstetricians and Gynecologists’ (ACOG) Committee on Clinical Consensus–Gynecology. General approaches to medical management of menstrual suppression: ACOG Clinical Consensus No. 3. <i>Obstet Gynecol</i>. 2022;140(3):528-541. doi:10.1097/AOG.0000000000004899<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/36356248/pubmed" id="36356248" target="_blank">36356248</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23635706">
<a name="23635706"></a>American College of Obstetricians and Gynecologists. ACOG committee opinion no. 557: Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. <i>Obstet Gynecol</i>. 2013;121(4):891-896.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/23635706/pubmed" id="23635706" target="_blank">23635706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31441825">
<a name="31441825"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Committee Opinion No. 785: ACOG screening and management of bleeding disorders in adolescents with heavy menstrual bleeding. <i>Obstet Gynecol</i>. 2019;134(3):e71-e83. doi:10.1097/AOG.0000000000003411<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/31441825/pubmed" id="31441825" target="_blank">31441825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva.1">
<a name="Teva.1"></a>Aygestin (norethindrone acetate) [prescribing information]. North Wales, PA: Teva Women's Health; October 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3117488">
<a name="3117488"></a>Betrabet SS, Shikary ZK, Toddywalla VS, Toddywalla SP, Patel D, Saxena BN. ICMR Task Force Study on hormonal contraception. Transfer of norethisterone (NET) and levonorgestrel (LNG) from a single tablet into the infant's circulation through the mother's milk. <i>Contraception</i>. 1987;35(6):517-522.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/3117488/pubmed" id="3117488" target="_blank">3117488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-513753">
<a name="513753"></a>Bhaskar A, Schulze PE, Acksteiner B, Laumas KR. Quantitative analysis of norethindrone in milk using deuterated carrier and gas chromatography-mass spectrometry. <i>J Steroid Biochem</i>. 1979;11(3):1323-1328.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/513753/pubmed" id="513753" target="_blank">513753</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31535715">
<a name="31535715"></a>Bofill Rodriguez M, Lethaby A, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. <i>Cochrane Database Syst Rev</i>. 2019;9(9):CD000400. doi: 10.1002/14651858.CD000400.pub4. PMID: 31535715; PMCID: PMC6751587.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/31535715/pubmed" id="31535715" target="_blank">31535715</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32304766">
<a name="32304766"></a>Bonnington A, Dianat S, Kerns J, et al. Society of Family Planning clinical recommendations: contraceptive counseling for transgender and gender diverse people who were female sex assigned at birth. <i>Contraception</i>. 2020;102(2):70-82. doi:10.1016/j.contraception.2020.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/32304766/pubmed" id="32304766" target="_blank">32304766</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Teva.2">
<a name="Teva.2"></a>Camila (norethindrone) [prescribing information]. North Wales, PA: Teva Pharmaceuticals; October 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29142910">
<a name="29142910"></a>Carswell JM, Roberts SA. Induction and maintenance of amenorrhea in transmasculine and nonbinary adolescents. <i>Transgend Health</i>. 2017;2(1):195-201. doi:10.1089/trgh.2017.0021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/29142910/pubmed" id="29142910" target="_blank">29142910</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23784109">
<a name="23784109"></a>Centers for Disease Control and Prevention (CDC). U.S. Selected Practice Recommendations for Contraceptive Use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition. <i>MMWR Recomm Rep</i>. 2013 Jun;62(RR-05):1-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/23784109/pubmed" id="23784109" target="_blank">23784109</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31606136">
<a name="31606136"></a>Chen LM, Blank SV, Burton E, Glass K, Penick E, Woodard T. Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine evidence-based review. <i>Fertil Steril</i>. 2019;112(6):1034-1042. doi:10.1016/j.fertnstert.2019.07.1349<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/31606136/pubmed" id="31606136" target="_blank">31606136</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27467319">
<a name="27467319"></a>Curtis KM, Jatlaoui TC, Tepper NK, et al. US selected practice recommendations for contraceptive use, 2016. <i>MMWR Recomm Rep</i>. 2016a;65(4):1‐66. doi:10.15585/mmwr.rr6504a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/27467319/pubmed" id="27467319" target="_blank">27467319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27467196">
<a name="27467196"></a>Curtis KM, Tepper NK, Jatlaoui TC, et al. US medical eligibility criteria for contraceptive use, 2016. <i>MMWR Recomm Rep</i>. 2016b;65(3):1‐103. doi:10.15585/mmwr.rr6503a1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/27467196/pubmed" id="27467196" target="_blank">27467196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32550522">
<a name="32550522"></a>Damm T, Lamvu G, Carrillo J, Ouyang C, Feranec J. Continuous vs. cyclic combined hormonal contraceptives for treatment of dysmenorrhea: a systematic review. <i>Contracept X</i>. 2019;1:100002. doi:10.1016/j.conx.2019.100002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/32550522/pubmed" id="32550522" target="_blank">32550522</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31138184">
<a name="31138184"></a>Dean J, Kramer KJ, Akbary F, et al. Norethindrone is superior to combined oral contraceptive pills in short-term delay of menses and onset of breakthrough bleeding: a randomized trial. <i>BMC Womens Health</i>. 2019;19(1):70. doi:10.1186/s12905-019-0766-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/31138184/pubmed" id="31138184" target="_blank">31138184</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Northstar.1">
<a name="Northstar.1"></a>Deblitane (norethindrone) [prescribing information]. Memphis, TN: Northstar Rx; March 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14043272">
<a name="14043272"></a>Fine E, Levin HM, McConnell EL Jr. Masculinization of female infants associated with norethindrone acetate. <i>Obstet Gynecol</i>. 1963;22:210-213.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/14043272/pubmed" id="14043272" target="_blank">14043272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6673900">
<a name="6673900"></a>Fotherby K, Towobola O, Muggeridge J, Elder MG. Norethisterone levels in maternal serum and milk after intramuscular injection of norethisterone oenanthate as a contraceptive. <i>Contraception</i>. 1983;28(5):405-411.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/6673900/pubmed" id="6673900" target="_blank">6673900</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28368518">
<a name="28368518"></a>Gordon CM, Ackerman KE, Berga SL, et al. Functional hypothalamic amenorrhea: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2017;102(5):1413-1439. doi:10.1210/jc.2017-00131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/28368518/pubmed" id="28368518" target="_blank">28368518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Glenmark.1">
<a name="Glenmark.1"></a>Heather (norethindrone) [prescribing information]. Mahwah, NJ: Glenmark Pharmaceuticals Inc USA; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aurobindo.1">
<a name="Aurobindo.1"></a>Incassia (norethindrone) [prescribing information]. East Windsor, NJ: Aurobindo Pharma USA Inc; August 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9647148">
<a name="9647148"></a>Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkilä A, Walker JJ, Cameron IT. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. <i>Br J Obstet Gynaecol</i>. 1998;105(6):592-598. doi:10.1111/j.1471-0528.1998.tb10172.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/9647148/pubmed" id="9647148" target="_blank">9647148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lupin.1">
<a name="Lupin.1"></a>Jencycla (norethindrone) [prescribing information]. Baltimore, MD: Lupin Pharmaceuticals Inc; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sandoz.1">
<a name="Sandoz.1"></a>Jencycla (norethindrone) [product monograph]. Boucherville, Quebec, Canada: Sandoz Canada Inc; June 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22154396">
<a name="22154396"></a>Kaser DJ, Missmer SA, Berry KF, Laufer MR. Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms. <i>J Pediatr Adolesc Gynecol</i>. 2012;25(2):105-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/22154396/pubmed" id="22154396" target="_blank">22154396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kaunitz.1">
<a name="Kaunitz.1"></a>Kaunitz AM. Abnormal uterine bleeding in nonpregnant reproductive-age patients: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30638562">
<a name="30638562"></a>Kirkham YA, Ornstein MP, Aggarwal A, McQuillan S. No. 313-menstrual suppression in special circumstances. <i>J Obstet Gynaecol Can</i>. 2019;41(2):e7-e17. doi:10.1016/j.jogc.2018.11.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/30638562/pubmed" id="30638562" target="_blank">30638562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.1">
<a name="Kliegman.1"></a>Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.3">
<a name="Kliegman.3"></a>Kliegman RM, Stanton BF, St. Geme JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kliegman.2">
<a name="Kliegman.2"></a>Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6213373">
<a name="6213373"></a>Koetsawang S, Nukulkarn P, Fotherby K, Shrimanker K, Mangalam M, Towobola K. Transfer of contraceptive steroids in milk of women using long-acting gestagens. <i>Contraception</i>. 1982;25(4):321-331.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/6213373/pubmed" id="6213373" target="_blank">6213373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31394072">
<a name="31394072"></a>Krempasky C, Harris M, Abern L, Grimstad F. Contraception across the transmasculine spectrum. <i>Am J Obstet Gynecol</i>. 2020;222(2):134-143. doi:10.1016/j.ajog.2019.07.043<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/31394072/pubmed" id="31394072" target="_blank">31394072</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9494772">
<a name="9494772"></a>Kuhnz W, Heuner A, Hümpel M, Seifert W, Michaelis K. In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women. <i>Contraception</i>. 1997;56(6):379-385.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/9494772/pubmed" id="9494772" target="_blank">9494772</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30742315">
<a name="30742315"></a>Lethaby A, Wise MR, Weterings MA, Bofill Rodriguez M, Brown J. Combined hormonal contraceptives for heavy menstrual bleeding. <i>Cochrane Database Syst Rev</i>. 2019;2(2):CD000154. doi:10.1002/14651858.CD000154.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/30742315/pubmed" id="30742315" target="_blank">30742315</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Afaxys.1">
<a name="Afaxys.1"></a>Lyza (norethindrone) [prescribing information]. Charleston, SC: Afaxys Pharma LLC; June 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Janssen.1">
<a name="Janssen.1"></a>Micronor (norethindrone) [product monograph]. Toronto, Ontario, Canada: Janssen; February 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Movisse.1">
<a name="Movisse.1"></a>Movisse (norethindrone) tablets, USP [product monograph]. Etobicoke, Ontario, Canada: Mylan Pharmaceuticals ULC; August 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Watson.1">
<a name="Watson.1"></a>Nora-BE (norethindrone) [prescribing information]. Parsippany, NJ: Watson Pharma; July 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ingenus.1">
<a name="Ingenus.1"></a>Norethindrone acetate tablets [prescribing information]. Orlando, FL: Ingenus Pharmaceuticals LLC; May 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Norlutate.1">
<a name="Norlutate.1"></a>Norlutate (norethindrone acetate) [product monograph]. Montreal, Quebec, Canada: Searchlight Pharma Inc; October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ohm.1">
<a name="Ohm.1"></a>Norlyroc (norethindrone) [prescribing information]. North Brunswick, NJ: Ohm Laboratories Inc; February 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Watson.2">
<a name="Watson.2"></a>Nor-QD (norethindrone) [prescribing information]. Parsippany, NJ: Watson Pharma; July 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6342899">
<a name="6342899"></a>Orme ML, Back DJ, Breckenridge AM. Clinical pharmacokinetics of oral contraceptive steroids. <i>Clin Pharmacokinet</i>. 1983;8(2):95-136.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/6342899/pubmed" id="6342899" target="_blank">6342899</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Janssen.2">
<a name="Janssen.2"></a>Ortho Micronor (norethindrone) [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals Inc; November 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24630080">
<a name="24630080"></a>Practice Committee of the American Society for Reproductive Medicine (ASRM). Treatment of pelvic pain associated with endometriosis: a committee opinion. <i>Fertil Steril</i>. 2014;101(4):927-935.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/24630080/pubmed" id="24630080" target="_blank">24630080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30980941">
<a name="30980941"></a>Pradhan S, Gomez-Lobo V. Hormonal contraceptives, intrauterine devices, gonadotropin-releasing hormone analogues and testosterone: menstrual suppression in special adolescent populations. <i>J Pediatr Adolesc Gynecol</i>. 2019;32(5S):S23-S29. doi:10.1016/j.jpag.2019.04.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/30980941/pubmed" id="30980941" target="_blank">30980941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34214420">
<a name="34214420"></a>Ramalho I, Leite H, Águas F. Abnormal uterine bleeding in adolescents: a multidisciplinary approach. <i>Acta Med Port</i>. 2021;34(4):291-297. doi:10.20344/amp.12829<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/34214420/pubmed" id="34214420" target="_blank">34214420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3586665">
<a name="3586665"></a>Sahlberg BL The characterization of sulphated metabolites of norethindrone in human milk after oral administration of contraceptive steroids. <i>J Steroid Biochem</i>. 1987;26(4):481-485.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/3586665/pubmed" id="3586665" target="_blank">3586665</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24315714">
<a name="24315714"></a>Santos M, Hendry D, Sangi-Haghpeykar H, Dietrich JE. Retrospective review of norethindrone use in adolescents. <i>J Pediatr Adolesc Gynecol</i>. 2014;27(1):41-44. doi:10.1016/j.jpag.2013.09.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/24315714/pubmed" id="24315714" target="_blank">24315714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-606500">
<a name="606500"></a>Saxena BN, Shrimanker K, Grudzinskas JG. Levels of contraceptive seroids in breast milk and plasma of lactating women. <i>Contraception</i>. 1977;16(6):605-613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/606500/pubmed" id="606500" target="_blank">606500</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12046776">
<a name="12046776"></a>Schrager S. Abnormal uterine bleeding associated with hormonal contraception. <i>Am Fam Physician</i>. 2002;65(10):2073-2080.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/12046776/pubmed" id="12046776" target="_blank">12046776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Northstar.2">
<a name="Northstar.2"></a>Sharobel (norethindrone) [prescribing information]. Memphis, TN: Northstar Rx; March 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7389350">
<a name="7389350"></a>Toddywalla VS, Mehta S, Virkar KD, Saxena BN. Release of 19-nor-testosterone type of contraceptive steroids through different drug delivery systems into serum and breast milk of lactating women. <i>Contraception</i>. 1980;21(3):217-223.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/7389350/pubmed" id="7389350" target="_blank">7389350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29386936">
<a name="29386936"></a>Villavicencio J, Allen RH. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. <i>Open Access J Contracept</i>. 2016;7:43-52. doi:10.2147/OAJC.S85565<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/norethindrone-pediatric-drug-information/abstract-text/29386936/pubmed" id="29386936" target="_blank">29386936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed January 5, 2024.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zacur.1">
<a name="Zacur.1"></a>Zacur HA. Managing an episode of acute uterine bleeding. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">https://www.uptodate.com</a>. Accessed October 20, 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12652 Version 432.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
